sLOX 1 Polyclonal Antibody, FITC Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-4206R-FITC-100uL |
| Product Name | sLOX 1 Polyclonal Antibody, FITC Conjugated |
| Applications |
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Reactivity | Human, Mouse |
| Predicted Reactivity | Rat |
| Specifications | |
| Conjugation | FITC |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human sLOX 1 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 4973 |
| Swiss Prot | P78380 |
| Subcellular location | Secreted, Cell membrane |
| Synonyms | LOX1; LOXIN; SLOX1; CLEC8A; SCARE1; Oxidized low-density lipoprotein receptor 1; Ox-LDL receptor 1; C-type lectin domain family 8 member A; Lectin-like oxidized LDL receptor 1; LOX-1; Lectin-like oxLDL receptor 1; hLOX-1; Lectin-type oxidized LDL receptor 1; OLR1 |
| Background | Receptor that mediates the recognition, internalization and degradation of oxidatively modified low density lipoprotein (oxLDL) by vascular endothelial cells. OxLDL is a marker of atherosclerosis that induces vascular endothelial cell activation and dysfunction, resulting in pro-inflammatory responses, pro-oxidative conditions and apoptosis. Its association with oxLDL induces the activation of NF-kappa-B through an increased production of intracellular reactive oxygen and a variety of pro-atherogenic cellular responses including a reduction of nitric oxide (NO) release, monocyte adhesion and apoptosis. In addition to binding oxLDL, it acts as a receptor for the HSP70 protein involved in antigen cross-presentation to naive T-cells in dendritic cells, thereby participating in cell-mediated antigen cross-presentation. Also involved in inflammatory process, by acting as a leukocyte-adhesion molecule at the vascular interface in endotoxin-induced inflammation. Also acts as a receptor for advanced glycation end (AGE) products, activated platelets, monocytes, apoptotic cells and both Gram-negative and Gram-positive bacteria. |
| Application Dilution | |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |
Frequently asked questions
Which applications is sLOX 1 Polyclonal Antibody, FITC Conjugated (bs-4206R-FITC) validated for, and at what dilution?
bs-4206R-FITC is validated for IF(IHC-P) (1:50-200); IF(IHC-F) (1:50-200); IF(ICC) (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does sLOX 1 Polyclonal Antibody, FITC Conjugated (bs-4206R-FITC) react with?
Tested reactivity: Human, Mouse. Predicted reactivity (expected from sequence homology but not yet tested): Rat.
How should bs-4206R-FITC be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise sLOX 1 Polyclonal Antibody, FITC Conjugated (bs-4206R-FITC)?
KLH conjugated synthetic peptide derived from human sLOX 1
What are the excitation and emission wavelengths of the FITC conjugate (bs-4206R-FITC)?
FITC on bs-4206R-FITC: excitation / emission 494nm/518nm.